STOCK TITAN

Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director Morrison Scott W received new equity awards tied to his service as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a right to receive one share of common stock, and 3,837 stock options to buy common stock at an exercise price of $64.34 per share.

Both the RSUs and options were granted as of the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous service. Following these grants, his reported holdings in these specific RSU and option awards are 2,417 and 3,837 units, respectively.

Positive

  • None.

Negative

  • None.
Insider Morrison Scott W
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,837 $0.00 --
Grant/Award Restricted Stock Units 2,417 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,837 shares (Direct); Restricted Stock Units — 2,417 shares (Direct)
Footnotes (1)
  1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
RSU grant size 2,417 RSUs Granted June 25, 2026 for non-employee director service
Stock option grant size 3,837 options Granted June 25, 2026 as annual director option
Option exercise price $64.34 per share Stock Option (right to buy) on Tarsus common stock
Option expiration date June 24, 2036 Expiration for director stock option grant
RSUs underlying shares 2,417 shares common stock Each RSU equals one share of common stock
Options underlying shares 3,837 shares common stock Shares subject to stock option grant
Restricted Stock Units financial
"He was granted 2,417 Restricted Stock Units, each representing a right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"He was granted 3,837 stock options to buy common stock at an exercise price"
non-employee director financial
"granted in connection with the Reporting Person's service as a non-employee director"
annual meeting of stockholders financial
"granted in connection with the Company's 2026 annual meeting of stockholders"
vest in full financial
"The RSUs vest in full on the one-year anniversary of the date of grant"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Tarsus Pharmaceuticals (TARS) director Morrison Scott W receive in this Form 4?

He received two equity awards: 2,417 Restricted Stock Units and 3,837 stock options in Tarsus Pharmaceuticals. Both awards compensate his service as a non-employee director in connection with the company’s 2026 annual meeting of stockholders.

How do the Restricted Stock Units granted to the TARS director work?

Each RSU represents a contingent right to receive one share of Tarsus common stock. The 2,417 RSUs were granted for his non-employee director service and will vest in full one year after the grant date, assuming continuous service on the board.

What are the key terms of the stock options granted to the TARS director?

He was granted 3,837 stock options with an exercise price of $64.34 per share, expiring on June 24, 2036. The options were issued as an annual grant for board service and will vest fully one year after the grant date, subject to continuous service.

Are the equity awards to the TARS director open-market purchases or compensation grants?

They are compensation-related grants, not open-market trades. The Form 4 uses transaction code “A” for grant or award acquisitions, reflecting routine annual equity compensation for a non-employee director rather than discretionary buying or selling in the market.

When will the TARS director’s RSUs and stock options vest?

Both awards will vest in full on the one-year anniversary of the June 25, 2026 grant date. Vesting is conditioned on his continuous service as a non-employee director through that one-year period following the grant.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morrison Scott W

(Last)(First)(Middle)
17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)
IRVINE CALIFORNIA 92673

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$64.3406/25/2026A3,837 (1)06/24/2036Common Stock3,837$03,837D
Restricted Stock Units(2)06/25/2026A2,417 (3) (3)Common Stock2,417$02,417D
Explanation of Responses:
1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Remarks:
/s/ Scott Sieckert, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)